Dan O’Connell

Daniel (Dan) is Head of Biology at Quotient, where he leads the company’s efforts to translate somatic genomics discoveries into validated targets for therapeutic development.

Before joining Quotient, Dan was Vice President of Genomics and Bioinformatics at Tome Biosciences, where he built and led interdisciplinary teams advancing CRISPR-directed integrases for both in vivo and ex vivo genome editing. Prior to that, he helped Intellia Therapeutics pioneer the first systemic CRISPR-based therapies, guiding the development of off-target detection methods and regulatory strategies that supported multiple clinical trials. Earlier in his career, Dan was a postdoctoral fellow and research scientist at the Broad Institute of MIT and Harvard, where his work focused on human genetics, inflammatory bowel disease, and functional genomics.

Dan received his PhD in genetics from Harvard Medical School and his BS in biological sciences from Cornell University.